Back to all papers

Predicting future brain atrophy based on longitudinal MRI.

July 28, 2026pubmed logopapers

Authors

Hadji M,Moradi E,Tohka J

Affiliations (1)

  • A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.

Abstract

BackgroundNeuron loss is a hallmark of neurodegenerative diseases and leads to brain atrophy detectable with magnetic resonance imaging (MRI). Accurate prediction of future atrophy is valuable for research in Alzheimer's disease (AD) and related dementias.ObjectiveThis study aimed to predict annualized percentage changes in hippocampal, ventricular, and total gray matter (TGM) volumes in individuals ranging from cognitively normal to dementia, and to evaluate whether longitudinal MRI-derived change measures improve prediction performance compared with single-time-point MRI information.MethodsUsing elastic net regression, we compared baseline models based on single-timepoint MRI information with longitudinal models incorporating prior MRI-derived change measures. Both approaches were evaluated as MRI-only and MRI + risk-factor variants, with risk factors including age, sex, <i>APOE4</i>, and diagnostic status.ResultsIn cross-validated analyses using the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, the longitudinal MRI + risk-factor model performed best, yielding Pearson correlations of 0.62 for hippocampal atrophy, 0.51 for ventricular enlargement, and 0.41 for TGM atrophy. Longitudinal models consistently outperformed single time-point models, and adding risk factors improved predictive performance beyond MRI alone. External validation using the Australian Imaging, Biomarkers and Lifestyle cohort confirmed these findings. Predicted atrophy outperformed present-day regional volumes in identifying individuals progressing from normal cognition to MCI/dementia and from MCI to dementia.ConclusionsMRI-derived longitudinal features enhance atrophy prediction, and predicted atrophy rates provide sensitive markers of future cognitive decline. These findings support the potential utility of predicted atrophy for cohort enrichment and therapeutic trial design.

Topics

Journal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.